VENTURE CAPITAL POST

Pfizer said that net compensation of chief executive officer Ian Read declined 23% in 2015 driven by a drop in stock awards. The chief's net compensation amounted to $18 million in 2015.

AstraZeneca is facing serious issues with regard to its executive salary after a profit cautioning. Investors want the company to link Pascal Soriot's pay with revenue target.

Valeant Pharmaceuticals, Inc. of Canada has partnered with AstraZeneca for the selling rights of psoriasis drug brodalumab. Amgen Inc. ended its partnership with AstraZeneca due to its worries over the drug's side effects.

AstraZeneca Plc (AZN.L) (AZN.N) would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body's immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday.

U.S. Pfizer is unlikely to come back with a fresh bid for AstraZeneca, the Anglo-Swedish pharmaceuticals group's top executive was quoted as saying by Swedish business daily Dagens Industri on Saturday.

Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara.

Pfizer (PFE.N) dampened investors' expectations of a renewed bid for AstraZeneca (AZN.L) on Monday by signing a major cancer drug deal with Germany's Merck KGaA (MRCG.DE), reducing the U.S. firm's need for Astra's products.

Recent U.S. tax changes have weakened the case for companies like Pfizer (PFE.N) to shift their tax bases overseas by striking so-called tax inversion deals, according to AstraZeneca's (AZN.L) chief executive.

AstraZeneca moved to strengthen its core oncology business on Tuesday with three deals designed to expand the British drugmaker's reach in treating tumors.

Pfizer Inc (PFE.N) reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc (AZN.L).

AstraZeneca's cancer drug pipeline, already on a roll following promising clinical trial results, could get a further boost next week from a European green light for an experimental medicine against ovarian cancer.

Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

Shares in drugmakers AstraZeneca (AZN.L) and Shire (SHP.L) both fell more than 5 percent on Tuesday after the U.S. Treasury took steps to curb "inversion" deals that allow companies to escape high U.S. taxes by reincorporating abroad.

Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Instead, he has spent the last three days immersed in heart science in Barcelona.

Britain-based AstraZeneca has formed a flagship deal with Medical Research Council or MRC to hopefully help the drugmaker revive research on new drugs, Reuters reported.